Acarbose vs Survodutide
A side-by-side research comparison of Acarbose and Survodutide across mechanism, dosing, half-life, benefits, side effects and research status.
Comparison table
| Attribute | Acarbose | Survodutide |
|---|---|---|
| Full name | Acarbose (Alpha-Glucosidase Inhibitor) | Survodutide (Dual GLP-1/Glucagon Agonist) |
| Category | Weight Management | Weight Management |
| Status | FDA-approved drug | Phase 3 Clinical Trial |
| Mechanism | Inhibits intestinal alpha-glucosidase enzymes, slowing the breakdown of complex carbohydrates into glucose. This flattens post-prandial glucose and insulin excursions and shifts undigested carbohydrate to the colon, feeding beneficial short-chain-fatty-acid-producing bacteria. | Activates GLP-1 receptors to reduce appetite while glucagon receptor activation increases hepatic fat oxidation, energy expenditure, and amino acid catabolism. |
| Molecular weight | 645.6 Da | 4,500 Da (approximate) |
| Half-life | ~2 hours | 5-7 days |
| Bioavailability | Very low systemic (~2%); acts locally in the gut | High (SubQ) |
| Typical dose | 25-100 mg per meal | 0.6-6.0 mg |
| Frequency | With carbohydrate-containing meals | Once weekly |
| Route | Oral tablet | Subcutaneous |
Acarbose reported benefits
- Flattens post-meal glucose spikes
- Improves glycemic variability
- Longevity signal (ITP data)
- Feeds beneficial gut bacteria
- Modest weight support
- Minimal systemic absorption
Survodutide reported benefits
- Significant weight loss (up to 19%)
- Liver fat reduction
- Increased energy expenditure
- MASH resolution potential
- Improved lipid profile
Related comparisons
Research and educational reference only. Not medical advice.